share_log

Inhibikase Therapeutics | SC 13D: Statement of acquisition of beneficial ownership by individuals-FiveT Investment Management Ltd(4.78%),FiveT Capital AG(4.78%)

Inhibikase Therapeutics | SC 13D:超过5%持股股东披露文件-FiveT Investment Management Ltd(4.78%),FiveT Capital AG(4.78%)

2023/02/24 12:27
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息